Romark’s investigational Covid-19 drug lowers disease progression in trial 15th April 2021 (Last Updated April 15th, 2021 17:33)
Romark has reported that initial results from a Phase III clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets, 300mg) demonstrated to reduce disease progression in mild or moderate Covid-19 patients.
The trial enrolled 1,092 subjects aged 12 years and above with respiratory symptoms consistent with Covid-19. Credit: Ewa Urban from Pixabay.
Share Article
Romark has reported that initial results from a Phase III clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets, 300mg) demonstrated to reduce disease progression in mild or moderate Covid-19 patients.
Reports of deaths after Covid vaccines up by 259 in one week, CDC data show
finalcall.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finalcall.com Daily Mail and Mail on Sunday newspapers.
Critical US Study Shows AstraZeneca Jab 79% Effective As Europeans Remain Skeptical
zerohedge.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zerohedge.com Daily Mail and Mail on Sunday newspapers.
Large U S trial confirms AstraZeneca Covid vaccine s effectiveness
delawarebusinessnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from delawarebusinessnow.com Daily Mail and Mail on Sunday newspapers.